Abstract
Non-small cell lung cancer (NSCLC), a leading cause of cancer-related death for men and women worldwide, exhibits a highly variable clinical course. Death may occur within a few weeks of diagnosis at one extreme, whereas other cases have apparently benign outcomes for periods of up to 20 years with no treatment (1). The current tumor-node-metastasis (TNM) staging system for NSCLC, which is based primarily on imaging studies and which serves as the principal guide for therapy, has significant limitations. For example, five-yr survival after “curative” resection for apparently localized, stage I NSCLC is only 46%, with death usually owing to recurrent or metastatic cancer (2). The reasons for this variability in clinical outcomes are largely unknown.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Marcus, P. M., Bergstralh, E. J., Fagerstrom, R. M., Williams, D. E., Fontana, R., Taylor, W. F., and Prorok, P. C. (2000) Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J. Natl. Cancer Inst. 92, 1308–1316.
Mountain, C. F. (1997) Revisions in the international system for staging lung cancer. Chest 111, 1710–1717.
Vogelstein, B. and Kinzler, K. W. (1993) The multi-step nature of cancer. Trends Genet, 9, 138–141.
Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 323, 561–565.
Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., et al. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53, 1–4.
Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52, 4828–4831.
Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., et al. (1993) bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med. 329, 690–694.
Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Torney, L., and Robinson, R. A. (1990) p185neu expression in human lung adenocarcinoma predicts shortened survival. Cancer Res. 50, 5184–5189.
Dazzi, H., Hasleton, P. S., Thatcher, N., Barnes, D. M., Wilkes, S., Swindell, R., and Lawson, R. A. M. (1989) Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br. J. Cancer 59, 746–749.
Miyake, M., Taki, T., Hitomi, S., and Hakomori, S.-I. (1992) Correlation of expression of H/Ley/Leb antigens with survival in patients with carcinoma of the lung. N. Engl. J. Med. 327, 14–18.
Pirinen, R., Hirvikoski, P., Bohm, J., Kellokoski, J., Moisio, K., Johansson, R., et al. (2000) Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in on-small cell lung carcinoma. Human Pathol. 31, 1088–1095.
Harpole, D. H., Jr, Herndon, J. E., II, Wolfe, W. G., Iglehart, J. D., and Marks, J. R. (1995) A prognostic model of recurrences and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55, 51–56.
Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., et al. (1995) Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J. Clin. Oncol. 13, 1893–1903.
Irie, K., Ishida, H., Furukawa, T., Koyanagi, K., and Miyamoto, Y. (1996) Clinicopathological study on primary lung cancer—immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis. Japn. J. Clin. Pathol. 44, 32–41.
D’Amico, T. A., Aloia, T. A, Moore, M.-B. H., Herndon, J. E., Brooks, K. R., Lau, C. L., and Harpole, D. H., Jr. (2000) Molecular biologic substaging of Sate I lung cancer according to gender and histology. Ann. Thorac. Surg. 69, 882–886.
Greatens, T. M., Niehans, G. A., Rubins, J. B., Jessurun, J., Kratzke, R. A., Maddaus, M. A., and Niewoehner, D. E. (1998) Do molecular markers predict survival in non-small cell lung cancer? Am. J. Respir. Crit. Care Med. 157, 1093–1097.
Huncharek, M., Muscat, J., and Geschwind, J.-F. (1999) K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20, 1507–1510.
Huncharek, M., Kupelnick, B., Geschwind, J. F., and Caubet, J. F. (2000) Prognostic significance of p53 mutations in non-small lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett. 153, 219–226.
Dickersin, K. (1990) The existence of publication bias and risk factors for its occurrence. JAMA 263, 1385–1389.
Misakian, A. L. and Bero, L. A. (1998) Publication bias and research on passive smoking: Comparison of published and unpublished studies. JAMA 280, 250–253.
Egger, M., Smith, G. D., Schneider, M., and Minder, C. (1997) Bias in meta-analysis detected by a simple graphical method. BMJ 315, 629–634.
Drummond, R. (1999) Fair conduct and fair reporting of clinical trials. JAMA 282, 1766–1768.
Counsell, C. E., Clarke, M. J., Slattery, J., and Sandercock, P. A. G. (1994) The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis. BMJ 309, 1677–1681.
Wang, T., Hopkins, D., Schmidt, C., Silva, S., Houghton, R., Takita, H., et al. (2000) Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene 19, 1519–1528.
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., et al. (2000) Distinct types of diffuse large B-cell Iymphoma identified by gene expression profiling. Nature 403, 503–511.
Maitra, A., Wistuba, I. I., Vimani, A. K., Sakaguchi, M., Park, I., Stucky, A., et al. (1999) Enrichment of epithelial cells for molecular studies. Nat. Med. 5, 459–463.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Niewoehner, D.E., Rubins, J.B. (2003). Clinical Utility of Tumor Markers in the Management of Non-Small Cell Lung Cancer. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicine™, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:135
Download citation
DOI: https://doi.org/10.1385/1-59259-324-0:135
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-920-9
Online ISBN: 978-1-59259-324-8
eBook Packages: Springer Protocols